Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 193, Issue 2, 2005, Pages 568-574

  Everett, Elise N ^a   Heuser, Cara C ^a   Pastore, Lisa M ^a   Anderson, Willie A ^a   Rice, Laurel W ^a   Irvin, William P ^a   Taylor, Peyton T ^a   Burrell, Matthew ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Division of Gynecologic Oncology ^*

Author keywords

CA 125; Chemotherapy; CT scan; Cytoreduction; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ASCITES; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OMENTUM; OVARY CARCINOMA; PERITONEUM; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 23844530171     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.03.058     Document Type: Conference Paper

References (25)

1. A. Jemal R.C. Tiwari T. Murray A. Ghafoor A. Samuels E. Ward Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. Pecorrelli S, Creasman WT, Pettersson F, Benedet JL, Shaperd JH, editors. FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat 1998;3:75-102.
3. R.E. Bristow R.S. Tomacruz D.K. Armstrong E.L. Trimble F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
4. C.T. Griffiths L.M. Parker A.F. Fuller Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer Cancer Treat Rep 63 1979 235 240
5. W.J. Hoskins W.P. McGuire M.F. Brady H.D. Homesley W.T. Creasman M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
6. T. Le G.V. Krepart R.J. Lotocki M.S. Heywood Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 67 1997 208 214
7. S.M. Eisenkop R.L. Friedman H.J. Wang Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study Gynecol Oncol 69 1998 103 108
8. S.S. Chen R. Bochner Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma Gynecol Oncol 20 1985 190 195
9. A.P. Heintz N.F. Hacker J.S. Berek T.P. Rose A.K. Munoz L.D. Lagasse Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity Obstet Gynecol 67 1986 783 788
10. P. Venesmaa O. Ylikorkala Morbidity and mortality associated with primary and repeat operations for ovarian cancer Obstet Gynecol 79 1992 168 172
11. P.E. Schwartz Neoadjuvant chemotherapy for the management of ovarian cancer Best Pract Res Clin Obstet Gynaecol 16 2002 585 596
12. K. Ushijima S. Ota K. Komai G. Matsuo S. Motoshima S. Honda Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer Int Surg 87 2002 185 190
13. M.U. Vrscaj S. Rakar Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study Eur J Gynaecol Oncol 23 2002 405 410
14. F. Kayikciog M.F. Kose N. Boran E. Caliskan G. Tulanay Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma Int J Gynecol Cancer 11 2001 466 470
15. W. Kuhn S. Rutke K. Spathe B. Schmalfeldt G. Florack B. von Hundelshausen Neoadjuvant chemotherapy followed by tumor debulking prolongs survival in patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma Cancer 92 2001 2585 2591
16. I.B. Vergote I. De Wever J. Decloedt W. Tjalma M. Van Gramberen P. van Dam Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer Semin Oncol 27 Suppl 7 2000 31 36
17. S. Kawamoto B.A. Urban E.K. Fishman CT of epithelial ovarian tumors Radiographics 19 1999 S85 S102
18. B.E. Nelson A.T. Rosenfield P.E. Schwartz Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma J Clin Oncol 11 1993 166 172
19. J.I. Meyer A.W. Kennedy R. Friedman A. Ayoub R.C. Zepp Ovarian carcinoma: value of CT in predicting success of debulking surgery AJR Am J Roentgenol 165 1995 875 878
20. R.E. Bristow L.R. Duska N.C. Lambrou E.K. Fishman M.J. O'Neill E.L. Trimble A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 89 2000 1532 1540
21. S.C. Dowdy S.A. Mullany K.R. Brandt B.J. Huppert W.A. Cliby The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 101 2004 346 352
22. I. Jacobs R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum Reprod 4 1989 1 12
23. D.S. Chi E.S. Venkatraman V. Masson W.J. Hoskins The ability of preoperative CA125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma Gynecol Oncol 77 2000 227 231
24. O. Gemer S. Segal A. Kopmar Preoperative CA-125 level as a predictor of non-optimal cytoreduction of advanced epithelial ovarian cancer Acta Obstet Gynecol Scand 80 2001 583 585
25. J.S. Berek Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125 Gynecol Oncol 77 2000 225 226